Organ chip technology accurately predicts chemotherapy response in esophageal adenocarcinoma patients
Esophagal adenocarcinoma (EAC), one of the two major forms of esophagal cancer, is the sixth deadliest cancer worldwide, for which no effective targeted therapy exists. Patients need to rely on chemotherapy as a standard-care, which is initiated before surgical intervention in the hope of shrinking or controlling the tumor as a so-called “newborn chemotherapy” (NACT). […]